Abstract Introduction: For routine staging of patients with primary breast cancer, clinical practice guidelines of many medical societies recommend chest X-ray, liver ultrasound and bone scan. With respect to expanding health care costs and patients' psychological distress it has been supposed, that there might be a group of breast cancer patients, who do not need these imaging studies. Methods: Four hundred and eighty-eight consecutive patients with primary breast cancer who had primary surgery at our institution and complete work-up for distant metastases including chest X-ray, liver ultrasound, and bone scan were studied. Results: We found distant metastases at the time of primary diagnosis in 19 patients (3.9%). Bone metastases were found in 2.7%, liver metastases in 1.0%, and pulmonary metastases in 0.4%. However, in breast tumors smaller than 1 cm, no metastatic lesions were found, whereas 18.2% of the patients with pT4 tumors had metastases. In 2.4% of screening imaging studies, metastases were ruled out by additional imaging. Conclusion: Based on our data and a review of the literature, we suggest that chest X-ray, liver ultrasound and bone scan can be omitted in the staging of asymptomatic patients with pT1a or pT1b disease.
Introduction
Screening of breast cancer patients for distant metastasis at the time of presentation is required for staging and subsequent management of these patients. In response to increasing demands for effectiveness of costs from government and private third-party payers, health care providers are asked to re-examine the current staging strategies and to optimize utilization of resources. On the other side as their patient's advocate, they have to do their best to exclude or detect metastatic lesions at initial presentation in order to avoid over-and undertreatment.
In breast cancer patients, metastases are found most frequently in bones, lung and liver, and therefore, the staging methods recommended are bone scan, chest X-ray and liver ultrasound. In case of unclear findings, further imaging studies such as computer tomography (CT) or magnetic resonance imaging (MRI) will be performed to confirm or rule out the presence of metastases.
The aim of this study was to determine the frequency and distribution pattern of metastases at the time of primary surgery, and to identify a group of breast cancer patients in whom imaging studies for staging can be omitted.
Patients and methods
From January 1996 to June 2001, 497 consecutive patients with primary breast cancer had surgery and subsequent therapy at the Division of Gynecology of the University Hospital of Zurich, Switzerland. Of these patients, 9 had incomplete staging due to simultaneous life limiting diseases or due to refusal, leaving 488 patients for further analysis. The mean age of these 488 patients was 60.9 years, ranging from 20 to 94 years. One hundred and forty (28.7%) patients were premenopausal and 348 (71.3%) postmenopausal. The patients were routinely staged with chest X-ray, liver ultrasound and bone scan. The detection rate of metastases was correlated with the size of the primary tumor as well as the presence of positive axillary lymph nodes. Staging was performed according to the American Joint Committee on Cancer (AJCC) classification system [7] . most frequent location of metastasis was bone (2.7%), followed by liver (1.0%) and lung (0.4%) ( Table 1) . Patients with pT1 tumor rarely had metastatic lesions. Only 2 of 106 (1.3%) patients with pT1c tumors had distant metastases, all of which were bone metastases. Moreover, both patients were node negative. In larger primary tumors, metastatic lesions occurred in lymph node positive breast cancer patients only. The highest percentage of distant metastases had pT4d tumors with 30%. Patient and tumor characteristics of the 7 patients with pT1-3 tumor and distant metastases are shown in Table 2 .
Axillary lymph node dissection was routinely performed in level I and II. In 268 (54.9%) patients the axillary lymph nodes were negative at primary therapy. Only 2 (0.7%) of these had distant metastases (bone metastases), detected by bone scan and confirmed with directed X-ray studies. No lung or liver metastases were found in node negative breast cancer patients at the time of primary surgery. Due to the suspicion of metastases in routine staging, 19 (7.1%) node negative patients had 21 additional radiologic studies performed: directed X-rays of bones in 10 cases, CT scan and/or MRI of the abdomen in 8 cases and CT scans of the chest in 3 cases. Metastatic lesions in all these 19 patients have been finally ruled out.
Positive axillary lymph nodes were found in 216 (44.3%) patients. In 4 patients the nodal status was not evaluable, mostly due to patients' refusal to axillary surgery or renunciation due to otherwise reduced life expectancy. None of these 4 patients had distant metastases.
In the 216 patients with node positive breast cancer, the diagnosis of distant metastases could be made by bone scan, liver ultrasound or chest X-ray in 9 patients (4.2%). Additional imaging studies were required in 22 of 216 patients (10.2%): 14 directed X-rays of bones, 5 CT scans and/or MRI of the abdomen, 5 CT scans of the chest and 1 CT scan of the bone. Only in 8 patients, metastases were confirmed. Hence, 17 (7.9%) of the node positive patients had distant metastases; one of these patients had both bone and liver metastases. Four patients with metastases had less then 4 positive axillary lymph nodes (23.5%). Of 28 patients with axillary micrometastasis (pN1a), one patient (3.6%) had detectable bone metastases. The number of false positive imaging studies routinely performed was high in both, node negative and node positive patients: In 4.3% of suspicious bone scans, 1.0% of suspicious chest X-ray and 1.8% of suspicious liver ultrasound, metastases were ruled out by additional imaging studies. Table 3 shows the correlation of the metastases and stage according to AJCC classification. Of the 5 patients with liver metastases, 3 had normal blood chemistry. The other 2 have had either elevated transaminases or elevated alkaline phosphatase. 
Discussion
Traditionally, chest X-ray, liver ultrasound and bone scan are performed in all patients with breast cancer at the time of first presentation to rule out lung, liver and bone metastases. This work-up is recommended by many clinical guidelines, e.g., the National Comprehensive Cancer Network [2] . Only few studies have been focusing on the necessity of these examinations in primary breast cancer, despite expanding health care costs. It has been hypothesized that staging examinations might be individualized according to tumor size, nodal status and stage. Bone is the most common location of distant metastases in breast cancer. In a review of nine studies, the rate of bone metastases at the time of primary surgery was 3.1% [8] . In our study, we found an overall rate of 2.7%. However, no patient with pT1a or pT1b disease was found to have distant metastases. Bone metastases were found in 1.3% of our patients with pT1 pN0 disease, which is in good agreement with the rates reported by Ciatto et al. [4] and Cox et al. [5] . In patients with presumable stage II disease, 1.3% of our patients had detectable distant metastases, which is similar to other reports [4, 5] . While 9.7% of our patients with presumable stage III disease had a skeletal involvement, Ciatto et al. [4] detected bone metastases in 1.2% and Cox et al. [5] in 16.2%.
Pulmonary metastases were present in only 2 of 488 patients (1.0%). Both patients had presumable stage III disease. This is similar to the rate of 0.3% reported by Ciatto et al. [4] . Chen et al. [3] reported an detection rate of 0.099% for asymptomatic lung metastases in 1003 patients. Although many anesthesiologists traditionally require chest X-ray before general anesthesia, there is no strong medical indication for routine preoperative chest X-ray in asymptomatic, otherwise healthy breast cancer patients [13] . Furthermore, chest X-ray has never been shown to improve outcome in the care of patients with clinical stage I and II breast cancer [3] . Our data support the view that chest X-ray may be eliminated in the routine staging for asymptomatic patients with stage I or II breast cancer.
Liver metastases at the time of primary therapy are described in 0.3 to 0.5% [1, 4] . In our study, we found liver metastases in 5 patients (1.0%). Accordant to the results of Ciatto et al. [4] , we never found liver metastases in patients with stage I breast cancer. In presumable stage II disease, we detected liver involvement in 1 patient (0.4%). In agreement with other studies [5, 6] , 4.3% of our patients with presumable stage III disease had liver metastases at the time of primary surgery. Myers et al. [8] and Ravaioli et al. [10, 11] conclude that liver ultrasound can be omitted in the work-up of stage I and II breast cancer unless symptoms or blood chemistry suggest liver metastases. With this strategy, we would have missed one patient with stage II disease with asymptomatic liver metastases and normal blood chemistry.
Based on our results and a review of the literature, it is reasonable and safe to reduce costs by omitting routine staging imaging studies of asymptomatic patients with pT1a and pT1b tumors. In patients with pT1c tumors routine staging yielded distant metastases in 1.3% of patients. Therefore, we believe that routine work-up for distant metastases should not be omitted in pT1c patients. Calculations on cost savings were made by Norum and Andreassen [9] . They suggested to screen patients in stage I and stage II breast cancer with less than five affected axillary lymph nodes by chest X-ray and blood tests only. According to their calculation, this strategy resulted in significant cost savings without influencing survival. By omitting imaging studies for asymptomatic patients with pT1a and pT1b disease, we recommend a more conservative strategy than others, since these publications accept a rate of missed metastatic disease up to 3% [8, 11, 12] . Using our approach, imaging studies for staging would have been omitted in 58 patients (11.9%) without missing distant metastases and two of 35 false-positive imaging studies would have been avoided (5.7%). 
